Deltex Sponsoring Evidence-Based Clinical Event

Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and latest evidence relating to Goal-Directed Hemodynamic Therapy (GDHT). Speakers at the event will include UCL Professors Monty Mythen and Mervyn Singer, both leading experts in their respective fields.

The timing is particularly appropriate, given the recent publication of the landmark FEDORA study that has demonstrated the positive effect of using ODM technology to guide fluid and vasoactive drug interventions.

The event will take place at the Great Russell Suite, Montague Hotel, London, WC1B 5BJ

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc investor event 11th September

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, has told DirectorsTalk that it will be hosting an investor event on 11 September 2017 following the publication of its interim results for the

    Deltex Medical Group Plc

    Deltex Medical, Nigel Keen Chairman Statement in full

    At the Annual General Meeting of Deltex Medical Group plc (LON:DEMG), the global leader in oesophageal Doppler monitoring (ODM), to be held today the Company’s Chairman, Nigel Keen, will make the following statement: The Company is

    Deltex Medical Group Plc

    Deltex Medical’s New Monitoring Platform Module

      Ewan Phillips, Chief Executive Officer of Deltex Medical Group plc (LON:DEMG) tells Proactive Investors they’ve launched a non-invasive High Definition Impedance Cardiography (HD-ICG) module in the UK.

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group Plc Looking pretty good

    Deltex Medical Group Plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about the benefits of the South Korean health authorities decision to increase the range of medical conditions for which they will reimburse the cost of